139 related articles for article (PubMed ID: 16162014)
1. Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors.
Deng BL; Hartman TL; Buckheit RW; Pannecouque C; De Clercq E; Fanwick PE; Cushman M
J Med Chem; 2005 Sep; 48(19):6140-55. PubMed ID: 16162014
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
Silvestri MA; Nagarajan M; De Clercq E; Pannecouque C; Cushman M
J Med Chem; 2004 Jun; 47(12):3149-62. PubMed ID: 15163195
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings.
Deng BL; Cullen MD; Zhou Z; Hartman TL; Buckheit RW; Pannecouque C; De Clercq E; Fanwick PE; Cushman M
Bioorg Med Chem; 2006 Apr; 14(7):2366-74. PubMed ID: 16321539
[TBL] [Abstract][Full Text] [Related]
4. Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
Hoshi A; Sakamoto T; Takayama J; Xuan M; Okazaki M; Hartman TL; Buckheit RW; Pannecouque C; Cushman M
Bioorg Med Chem; 2016 Jul; 24(13):3006-3022. PubMed ID: 27234889
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
Cullen MD; Deng BL; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; Clercq ED; Cushman M
J Med Chem; 2007 Oct; 50(20):4854-67. PubMed ID: 17803290
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of a non-nucleoside reverse transcriptase inhibitor in the alkenyldiarylmethane (ADAM) series with optimized potency and therapeutic index.
Cushman M; Casimiro-Garcia A; Williamson K; Rice WG
Bioorg Med Chem Lett; 1998 Jan; 8(2):195-8. PubMed ID: 9871653
[TBL] [Abstract][Full Text] [Related]
7. Solid-phase synthesis of the alkenyldiarylmethane (ADAM) series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
Xu G; Loftus TL; Wargo H; Turpin JA; Buckheit RW; Cushman M
J Org Chem; 2001 Sep; 66(18):5958-64. PubMed ID: 11529718
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems.
Sakamoto T; Cullen MD; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
J Med Chem; 2007 Jul; 50(14):3314-21. PubMed ID: 17579385
[TBL] [Abstract][Full Text] [Related]
9. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
[TBL] [Abstract][Full Text] [Related]
10. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
[TBL] [Abstract][Full Text] [Related]
11. Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
Casimiro-Garcia A; Micklatcher M; Turpin JA; Stup TL; Watson K; Buckheit RW; Cushman M
J Med Chem; 1999 Nov; 42(23):4861-74. PubMed ID: 10579849
[TBL] [Abstract][Full Text] [Related]
12. Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Chan JH; Freeman GA; Tidwell JH; Romines KR; Schaller LT; Cowan JR; Gonzales SS; Lowell GS; Andrews CW; Reynolds DJ; St Clair M; Hazen RJ; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Koszalka GW; Boone LR
J Med Chem; 2004 Feb; 47(5):1175-82. PubMed ID: 14971897
[TBL] [Abstract][Full Text] [Related]
13. The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.
Tucker TJ; Saggar S; Sisko JT; Tynebor RM; Williams TM; Felock PJ; Flynn JA; Lai MT; Liang Y; McGaughey G; Liu M; Miller M; Moyer G; Munshi V; Perlow-Poehnelt R; Prasad S; Sanchez R; Torrent M; Vacca JP; Wan BL; Yan Y
Bioorg Med Chem Lett; 2008 May; 18(9):2959-66. PubMed ID: 18396399
[TBL] [Abstract][Full Text] [Related]
14. Replacement of the metabolically labile methyl esters in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors with isoxazolone, isoxazole, oxazolone, or cyano substituents.
Deng BL; Hartman TL; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
J Med Chem; 2006 Aug; 49(17):5316-23. PubMed ID: 16913721
[TBL] [Abstract][Full Text] [Related]
15. Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis.
Kirschberg TA; Balakrishnan M; Huang W; Hluhanich R; Kutty N; Liclican AC; McColl DJ; Squires NH; Lansdon EB
Bioorg Med Chem Lett; 2008 Feb; 18(3):1131-4. PubMed ID: 18083512
[TBL] [Abstract][Full Text] [Related]
16. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
[TBL] [Abstract][Full Text] [Related]
17. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Golebiewski WM; Graham L; Turpin JA; Rice WG; Fliakas-Boltz V; Buckheit RW
J Med Chem; 1996 Aug; 39(16):3217-27. PubMed ID: 8759644
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity.
Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers M; Van Aken KJ; Arnold E; Das K; Kilonda A; Hoornaert GJ; Compernolle F; Cegla M; Azzam RA; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Janssen PA
J Med Chem; 2005 Mar; 48(6):1910-8. PubMed ID: 15771435
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.
Feng XQ; Zeng ZS; Liang YH; Chen FE; Pannecouque C; Balzarini J; De Clercq E
Bioorg Med Chem; 2010 Apr; 18(7):2370-4. PubMed ID: 20307984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
